surpass cvot tirzepatide results Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT | Diabetes Therapy Don't Miss a Beat: SURPASS-CVOT

For my patients in Lafayette, the Bay Area, or anywhere in California via telemedicine , this discussion is simplified and clarified so your questions, anxiety and fear are resolved with the right science

The results were consistent with the overall SELECT trial findings and showed a numerically larger risk reduction in the perimenopausal women (42% lower risk compared to placebo) compared to the postmenopausal women (13% lower risk compared to placebo), although the difference between the groups was not statistically significant

Sophocleous A, Idris AI (2014) Rodent models of osteoporosis

doi: 10.1016/j.vetpar.2023.110011 32 Witko-SarsatVNguyen-KhoaTJungersPDrekeTBDescamps-LatschaB